Posted by Michael Wonder on 22 Mar 2026
IntraBio announces submission of supplemental new drug application for levacetylleucine for ataxia-telangiectasia
20 March 2026 - IntraBio today announced the submission of a supplemental new drug application to the US FDA for levacetylleucine for the treatment of ataxia-telangiectasia, a rare, progressive, inherited neurodegenerative disorder.
This submission represents the first regulatory application submitted to the US FDA seeking approval of a therapy for the treatment of ataxia-telangiectasia.
